An interventional study of Gut directed hypnotherapy via telephone intervention and Educational recording in Disorders of Gut-brain Interaction, Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome, sponsored by Stanford University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Stanford University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Inflammatory Bowel Diseases by Stanford University — 5 open to participants now, 5 under way, none of them phase 3. Inflammatory Bowel Diseases · Stanford University.
Among the 10 studies in Inflammatory Bowel Diseases by Stanford University, this one is the only one that started in 2026, is one of 6 with no phase, and was the 10th registered.
1,555 studies on the registry are indexed under Inflammatory Bowel Diseases; 425 are open to participants now.
Browse Inflammatory Bowel Diseases studies →5 of the 10 studies in Inflammatory Bowel Diseases by Stanford University are open now, in 1 country. Recruiting first, the newest first:
Stanford University · Sites in United States
Ages 18–80 · Healthy volunteers
Stanford University · Sites in United States
Ages 18–70
Stanford University · Sites in United States
Ages 18+
Stanford University
Ages 18–100 · Healthy volunteers
By country, each count listing its studies:
Of the 276 Inflammatory Bowel Diseases studies recruiting now, 134 (49%) set no upper age limit and 114 (41%) stop at 75 or younger; 75 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 26 is below the median of 68 across 875 interventional studies indexed under Inflammatory Bowel Diseases.
Median enrollment 21 across the 9 interventional studies, 150 across the 1 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Stanford University is the lead sponsor of 2,171 studies on the registry; 425 are open to participants now.
Of its 268 completed or terminated interventional studies of FDA-regulated products, 207 (77%) have results posted.
2 of the studies in Inflammatory Bowel Diseases by Stanford University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05912387Stanford UniversityStatin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study | 2027-05-31 |
| NCT07676136Stanford UniversityA Pilot Study Using Gut-Directed Hypnotherapy for Hospitalized Patients | 2027-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies in Inflammatory Bowel Diseases by Stanford University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to compare the effectiveness of recorded gut-directed hypnosis to an educational recording in people with chronic problems in their gastrointestinal (GI) system. Patients who are hospitalized at Stanford Hospital for worsening pain and/or nausea will be considered for enrollment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will undergo gut-directed hypnotherapy via a phone intervention (10 minute recording, at least once daily while hospitalized) and for as much as participant would like for the 3 month duration of the study.
Behavioral: Gut directed hypnotherapy via telephone intervention
Participants will listen to educational recording (10 minute recording, at least once daily while hospitalized) and for as much as participant would like for the 3 month duration of the study.
Behavioral: Educational recording
Participants will undergo a self-directed gut-directed hypnosis intervention over the telephone.
Participants will listen to educational material over the telephone about their gastrointestinal symptoms.
Recruitment rate
Recruitment rate is the proportion enrolled among eligible patients approached.
Time frame: Up to 1 year.
Number of participants who adhered to intervention
Proportion of participants completing ≥1 hypnosis session during hospitalization and total number of listens
Time frame: 3 months.
Retention rate
Retention rate is defined as survey completion at baseline, 1 week, 1 month, and 3 months.
Time frame: 3 months.
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2026 (actual). Primary completion is estimated for Jul 2027, 8 months after the start.
Of 285 non-industry interventional studies with no phase under Inflammatory Bowel Diseases, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's planned 8 months is below that.
Counting every sponsor, half of 299 studies reached it within 26 months; a quarter within 14 and three quarters within 50.
Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Nov 2026, on Nov 18, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.